ArticleFrontiers in public health2022

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.

Rui Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.